Evidence map›Paper›PMID 39821052›Full record

ArticleAAPS PharmSciTech2025

Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants.

Hasan Jubaer, Sarah Strickler, Dale Farkas, Caleb Dalton, Mohammad A M Momin, Kelley M Dodson, Michael Hindle, Worth Longest

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hasan JubaerDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States of America.
Sarah StricklerDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States of America.
Dale FarkasDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States of America.
Caleb DaltonDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States of America.
Mohammad A M MominDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States of America.
Kelley M DodsonDepartment of Otolaryngology, Virginia Commonwealth University, Richmond, VA, United States of America.
Michael HindleDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States of America.
Worth LongestDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States of America. pwlongest@vcu.edu.ORCID http://orcid.org/0000-0003-4939-5691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The administration of surfactant aerosol therapy to preterm infants receiving continuous positive airway pressure (CPAP) respiratory support is highly challenging due to small flow passages, relatively high ventilation flow rates, rapid breathing and small inhalation volumes. To overcome these challenges, the objective of this study was to implement a validated computational fluid dynamics (CFD) model and develop an overlay nasal prong interface design for use with CPAP respiratory support that enables high efficiency powder aerosol delivery to the lungs of preterm infants when needed (i.e., on-demand) and can remain in place without increasing the work of breathing compared with a baseline CPAP interface. Realistic in vitro experiments were first conducted to generate baseline validation data, and then the CFD model, once validated, was used to explore key design parameters across a range of preterm infant nose-throat geometries and aerosol delivery conditions. The most important factors for efficient aerosol delivery were shown to be (i) maintaining the aerosol delivery flow rate below the tracheal flow rate (to minimize CPAP line loss) and (ii) concentrating the aerosol within the first portion of the inhalation waveform. An optimized design was shown to deliver approximately 37-60% of the nominal dose through the system and to the lungs with low intersubject variability (1050-2200 g infants) across two modes of device actuation (automated and manual) with room for further improvement. Ergonomic curvatures and streamlining of the prong geometries were also found to reduce work of breathing and flow resistance compared with a commercial alternative.

Indexed as

Continuous Positive Airway PressurePulmonary SurfactantsAdministration, InhalationAerosolsDrug Delivery SystemsEquipment DesignHumansHydrodynamicsInfant, NewbornInfant, PrematureLungAerosolsPulmonary SurfactantsCFDCPAP interfacepharmaceutical aerosol deliverypreterm infantssurfactant aerosol therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.